Health technology company BioWave Corp reported on Tuesday the availability of the new US FDA cleared, over the counter version of its popular, non-opioid, patented, pain relief technology, the BioWaveGO.
The company said the BioWave products are Professional Athlete proven and US Military trusted and is currently used by most NFL, NBA, NHL, and MLB teams, 160+ college programmes, over 80 VA hospitals, as well as by pain doctors nationally.
BioWave is available in a wearable, non-prescription strength to help anyone in acute or chronic pain lead a fuller and active pain-free life. BioWave technology has been proven effective, significantly reducing pain from just one 30-minute treatment and comes with a 30-day money back guarantee. The US FDA-cleared, high-frequency neurostimulation technology delivers soothing therapeutic signals through the skin into deep tissue, blocking pain signals at the source, added the company.
In conjunction, the company stated the development of the new BioWaveGO OTC product is the natural evolution of a patented neurostimulator pain relief technology that was developed over more than ten years. BioWaveGo is available for purchase on the BioWave website and under Federal Supply Schedule contract number V797D-70205.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML